Related Experiment Video
Updated: May 26, 2026
07:32
Assessing Iron Deposition in the Brains of 5xFAD Mice by Perls'/DAB Staining
Published on: May 23, 2025
Increased 5S rRNA oxidation in Alzheimer's disease
Qunxing Ding1, Haiyan Zhu, Bing Zhang
1Department of Biological Sciences, Kent State University at East Liverpool, East Liverpool, OH 43920, USA. qding@kent.edu
Journal of Alzheimer'S Disease : JAD
|January 11, 2012
Summary
Oxidative stress impacts Alzheimer's disease (AD). In AD brains, 5S ribosomal RNA (rRNA) shows increased oxidation and decreased levels, particularly free 5S rRNA, suggesting its role in neurodegeneration.
Area of Science:
- Neuroscience
- Molecular Biology
- Biochemistry
Background:
- Oxidative stress is implicated in neurodegenerative diseases like Alzheimer's disease (AD).
- Ribosomal RNA (rRNA), abundant in cells, is vulnerable to oxidative damage in the brain.
- Previous studies noted reduced total rRNA and increased oxidation in AD brains.
Purpose of the Study:
- To investigate alterations in 5S ribosomal RNA (rRNA) in various brain regions of Alzheimer's disease (AD) subjects.
- To examine different molecular pools of 5S rRNA, including free, ribosome-integrated, cytoplasmic, and nuclear forms.
- To assess the impact of oxidative stress on 5S rRNA in the context of neurodegeneration.
Main Methods:
- Analysis of 5S rRNA levels and oxidation in multiple brain regions (inferior parietal lobule, temporal regions, cerebellum) from AD and age-matched control subjects.
- Quantification of free, ribosome-integrated, cytoplasmic, and nuclear 5S rRNA pools.
- Measurement of 5S rRNA oxidation using molecular assays.
Main Results:
- Significantly decreased levels of free 5S rRNA were observed in the temporal pole of AD subjects.
- Oxidation of both ribosome-integrated and free 5S rRNA was significantly elevated across multiple brain regions in AD patients compared to controls.
- Increased oxidized 5S rRNA was detected in both the cytoplasm and nucleus of brain cells from AD subjects.
Conclusions:
- Increased oxidation of 5S rRNA, particularly the free form, is a prominent feature in the brains of Alzheimer's disease patients.
- These findings suggest that oxidative damage to 5S rRNA may contribute to the neurodegenerative processes observed in AD.
- Further research into the role of 5S rRNA oxidation in AD pathogenesis is warranted.
Related Concept Videos
01:23Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
01:29Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
01:26Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
01:22Dementia l: Introduction
Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
01:24Parkinson Disease ll: Pathophysiology
Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...